Calbindin 2 as a Novel Biomarker and Therapeutic Target for Abdominal Aortic Aneurysm: Integrative Analysis of Human Proteomes and Genetics
This study identifies CALB2 as being associated with an increased risk of AAA and suggests that i might be a novel biomarker and therapeutic molecule for AAA management. Lenalidomide and genistein hold promising potential as treatments for patients with AAA.
Authors
- Tongtong Yang (ORCID: https://orcid.org/0000-0002-2553-0732)
- Lingfeng Gu (ORCID: https://orcid.org/0000-0003-0021-4722)
- Xudong Han (ORCID: https://orcid.org/0000-0001-7961-5179)
- Liping Xie (ORCID: https://orcid.org/0000-0001-6440-0239)
- Jiawen Chen (ORCID: https://orcid.org/0000-0001-7101-3034)
- Hao Wang (ORCID: https://orcid.org/0000-0002-1053-5303)
- Jiayi Chen (ORCID: https://orcid.org/0000-0001-6417-290X)
- Liansheng Wang (ORCID: https://orcid.org/0000-0001-8538-6560)
- Sibo Wang (ORCID: https://orcid.org/0000-0002-3204-2710)
- Ye He (ORCID: https://orcid.org/0009-0005-2519-1346)
- Yi Bao (ORCID: https://orcid.org/0000-0002-2175-2688)
- Xinying Shi
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1161/jaha.124.039195
- Citations
- 4
- Primary Topic
- Aortic aneurysm repair treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.07